Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
NCT07609875Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Jan 2027
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing HS-10522 with HS-10522 Placebo (2 arms). Primary endpoint: Incidence of adverse events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HS-10522
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07609875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609875.